HENDERSON, Nev. —  Leading Edge Pharms, a biotechnology company developing novel cannabinoid therapies and innovative delivery platforms, Wednesday announced its partnership with Independent Pharmacy Alliance (IPA), a trade group and retail pharmacy buying cooperative, to make LEP’s Hemp/CBD-based Cannavera Topical Pain Relief products available to IPA’s 3,100 member pharmacies, located in New York, New Jersey, Connecticut and Pennsylvania.

“Consumers are looking to cannabinoid therapies as a new, natural and effective way to treat localized pain, and it is the responsibility of the pharmacy industry to ensure we are providing  products supported by scientific research,” said John Giampolo, chief executive officer and president of IPA. “Through our partnership with Leading Edge Pharms, our member pharmacies now have access to a safe, reliable, high quality product, for which pharmacists can confidently provide their recommendation.”

Through this agreement, LEP will offer IPA members preferred pricing on its Cannavera topical pain relief products, including its oil, lotion, crème, liquid spray and ointment.

“IPA is ahead of the pharmacy curve in identifying quality Hemp derived cannabinoid based products and are actively delivering them to the shelves. Our shared goal is to provide affordable, natural, safe and effective pain relief solutions that may ultimately serve as an alternative to opioid medications as a first step in pain management,” said David Chadwick, chief executive officer of Leading Edge Pharms. “We are confident that our products can safely help to improve the quality of life for consumers managing chronic pain.”